Insider Trading Arrangements |
3 Months Ended |
|---|---|
|
Sep. 30, 2026
shares
| |
| Trading Arrangements, by Individual | |
| Material Terms of Trading Arrangement | Rule 10b5-1 Trading Arrangements. During the three months ended September 30, 2026, our officers (as defined in Rule 16a-1(f) under the Exchange Act) set forth below adopted or terminated a “Rule 10b5-1 trading arrangement” as that term is defined in Item 408(a) of Regulation S-K, all of which were entered into during an open trading window in accordance with our Securities Trading Policy and all of which were intended to satisfy Rule 10b5-1(c). • On August 12, 2026, Jay R. Luly, Ph.D., our President, Chief Executive Officer and Director, adopted a Rule 10b5-1 trading plan providing for the sale of up to 96,005 shares of our common stock, including shares vested under performance stock units and restricted stock units, as well as shares vesting under outstanding stock options which expire in November 2027, so long as the market price of our common stock is higher than certain minimum threshold prices specified in the plan in various periods between , 2027, or such earlier date as all authorized sales under the plan are completed. • On August 13, 2026, Tara L. Kieffer, Ph.D., our Chief Operating Officer, adopted a Rule 10b5-1 trading plan providing for the sale of up to 83,419 shares of our common stock, including shares vested under performance stock units and restricted stock units, as well as shares vesting under outstanding stock options, so long as the market price of our common stock is higher than certain minimum threshold prices specified in the plan in various periods between, or such earlier date as all authorized sales under the plan are completed. • On September 9, 2026, Scott Rottinghaus, M.D., our Chief Medical Officer, adopted a Rule 10b5-1 trading plan providing for the sale of up to 22,037 shares of our common stock, including shares vested under performance stock units and restricted stock units, so long as the market price of our common stock is higher than certain minimum threshold prices specified in the plan in various periods between , or such earlier date as all authorized sales under the plan are completed. Except as set forth above, none of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-rule 10b5-1 trading arrangement,” as each term is defined in item 408(a) of Regulation S-K. |
| Rule 10b5-1 Arrangement Adopted | false |
| Non-Rule 10b5-1 Arrangement Adopted | false |
| Rule 10b5-1 Arrangement Terminated | false |
| Non-Rule 10b5-1 Arrangement Terminated | false |
| Jay R. Luly | |
| Trading Arrangements, by Individual | |
| Name | Jay R. Luly |
| Title | President, Chief Executive Officer and Director |
| Rule 10b5-1 Arrangement Adopted | true |
| Adoption Date | August 12, 2026 |
| Arrangement Duration | 162 days |
| Aggregate Available | 96,005 |
| Tara L. Kieffer | |
| Trading Arrangements, by Individual | |
| Name | Tara L. Kieffer |
| Title | Chief Operating Officer |
| Rule 10b5-1 Arrangement Adopted | true |
| Adoption Date | August 13, 2026 |
| Arrangement Duration | 370 days |
| Aggregate Available | 83,419 |
| Scott Rottinghaus | |
| Trading Arrangements, by Individual | |
| Name | Scott Rottinghaus |
| Title | Chief Medical Officer |
| Rule 10b5-1 Arrangement Adopted | true |
| Adoption Date | September 9, 2026 |
| Arrangement Duration | 123 days |
| Aggregate Available | 22,037 |